Total Payments
$4,272
2024 Payments
$74.09
Companies
44
Transactions
264
Medicare Patients
846
Medicare Billing
$157,889
Payment Breakdown by Category
Food & Beverage$4,134 (96.8%)
Education$138.07 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,134 | 260 | 96.8% |
| Education | $138.07 | 4 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $386.97 | 23 | $0 (2023) |
| Daiichi Sankyo Inc. | $384.29 | 26 | $0 (2023) |
| Genentech USA, Inc. | $306.82 | 19 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $284.78 | 19 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $282.29 | 17 | $0 (2023) |
| Seagen Inc. | $185.57 | 12 | $0 (2023) |
| PFIZER INC. | $168.11 | 12 | $0 (2023) |
| Amgen Inc. | $162.76 | 10 | $0 (2023) |
| Janssen Biotech, Inc. | $160.21 | 10 | $0 (2023) |
| Celgene Corporation | $159.06 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74.09 | 4 | Regeneron Healthcare Solutions, Inc. ($38.13) |
| 2023 | $614.25 | 32 | Daiichi Sankyo Inc. ($70.70) |
| 2022 | $688.14 | 43 | Amgen Inc. ($105.18) |
| 2021 | $336.51 | 24 | Daiichi Sankyo Inc. ($120.68) |
| 2020 | $404.68 | 29 | Daiichi Sankyo Inc. ($71.40) |
| 2019 | $935.16 | 56 | Merck Sharp & Dohme Corporation ($136.36) |
| 2018 | $423.04 | 30 | Bayer HealthCare Pharmaceuticals Inc. ($83.10) |
| 2017 | $796.25 | 46 | Genentech USA, Inc. ($155.99) |
All Payment Transactions
264 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.00 | General |
| 07/02/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: ONCOLOGY | ||||||
| 06/09/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $22.59 | General |
| 06/07/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Oncology | ||||||
| 06/05/2023 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Oncology | ||||||
| 05/31/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $33.57 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.20 | General |
| Category: Hematology | ||||||
| 05/12/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2023 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: BioOncology | ||||||
| 05/09/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Oncology | ||||||
| 04/26/2023 | Boston Scientific Corporation | EkoSonic (Device) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: EkoSonic_PI | ||||||
| 04/26/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: Iron Deficiency Anemia | ||||||
| 04/24/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $14.46 | General |
| Category: Hematology/Oncology | ||||||
| 04/18/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Oncology | ||||||
| 04/11/2023 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: Oncology / Rare Diseases | ||||||
| 03/31/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 03/30/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/27/2023 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 03/25/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $13.41 | General |
| Category: Oncology | ||||||
| 03/21/2023 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Oncology | ||||||
| 03/17/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.66 | General |
| Category: Oncology | ||||||
| 03/14/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 125 | 202 | $44,974 | $16,131 |
| 2022 | 4 | 204 | 470 | $101,640 | $39,814 |
| 2021 | 4 | 242 | 546 | $112,186 | $51,786 |
| 2020 | 4 | 275 | 607 | $115,318 | $50,158 |
Total Patients
846
Total Services
1,825
Medicare Billing
$157,889
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 82 | 153 | $30,780 | $11,813 | 38.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,856 | $1,779 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 18 | 20 | $5,380 | $1,390 | 25.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 17 | $2,958 | $1,150 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 108 | 322 | $60,858 | $25,745 | 42.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 41 | $20,008 | $6,809 | 34.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 35 | 79 | $13,746 | $4,751 | 34.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 28 | $7,028 | $2,509 | 35.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 83 | 209 | $40,261 | $21,472 | 53.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 91 | 225 | $42,525 | $19,987 | 47.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 28 | $13,664 | $4,776 | 35.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 68 | $11,832 | $4,126 | 34.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 16 | 16 | $3,904 | $1,425 | 36.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 124 | 350 | $66,226 | $31,697 | 47.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 57 | 146 | $25,404 | $8,979 | 35.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 39 | 44 | $14,257 | $5,036 | 35.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 41 | 53 | $6,633 | $3,490 | 52.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 14 | $2,798 | $955.46 | 34.1% |
About Dr. Barry Levinson, MD
Dr. Barry Levinson, MD is a Medical Oncology healthcare provider based in Elizabeth, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043301641.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Levinson, MD has received a total of $4,272 in payments from pharmaceutical and medical device companies, with $74.09 received in 2024. These payments were reported across 264 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($4,134).
As a Medicare-enrolled provider, Levinson has provided services to 846 Medicare beneficiaries, totaling 1,825 services with total Medicare billing of $157,889. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Elizabeth, NJ
- Active Since 09/27/2006
- Last Updated 01/07/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1043301641
Products in Payments
- KEYTRUDA (Biological) $313.07
- INJECTAFER (Drug) $304.68
- OPDIVO (Biological) $232.03
- LIBTAYO (Biological) $164.06
- TUKYSA (Drug) $130.95
- Stivarga (Drug) $125.55
- Xofigo (Drug) $121.96
- Avastin (Biological) $118.34
- JAKAFI (Drug) $111.50
- IMBRUVICA (Drug) $110.19
- KISQALI (Drug) $102.62
- REBLOZYL (Biological) $92.38
- Lenvima (Drug) $87.20
- DARZALEX (Biological) $86.32
- IBRANCE (Drug) $83.05
- Lonsurf (Drug) $68.79
- LUMAKRAS (Drug) $68.25
- GILOTRIF (Drug) $67.49
- VERZENIO (Drug) $60.68
- PADCEV (Biological) $54.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.